Osilodrostat: Novel Therapy for Cushing Syndrome Management

Abstract

Osilodrostat represents a promising advancement in the treatment landscape for Cushing syndrome, a rare disorder characterized by excessive cortisol production. Approved by regulatory authorities in recent years, Osilodrostat offers a targeted approach to managing this challenging condition, providing new hope for patients who have limited treatment options. The drug’s mechanism of action distinguishes it from traditional therapies, potentially offering new hope for patients with difficult-to-treat forms of Cushing syndrome. Ongoing research aims to further explore its long-term safety profile and its role in combination therapies, highlighting Osilodrostat as a promising advancement in the
management of this challenging endocrine condition.

How to cite this article:
Thakur K, Shah P. Osilodrostat: Novel Therapy
for Cushing Syndrome Management. Int J Adv
Res Pharm Edu 2024; 6(1): 26-28.